Prot #ACP-103-035: A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Project: Research project

Project Details

StatusFinished
Effective start/end date9/12/176/30/22

Funding

  • Quintiles, Inc. ((OE) Prot #ACP-103-035 // (OE) Prot #ACP-103-035)
  • ACADIA Pharmaceuticals Inc. ((OE) Prot #ACP-103-035 // (OE) Prot #ACP-103-035)